FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
MONDAY, June 20, 2022 (HealthDay News) -- Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Approved dosing for Skyrizi for the treatment of CD is 600 mg by intravenous infusion over at least one hour at week 0, week 4, and week 8, followed by 360 mg self-administered by subcutaneous injection with an on-body injector at week 12 and every eight weeks thereafter.
The company reported that in two induction trials and one maintenance clinical trial, Skyrizi demonstrated significant improvements in endoscopic response (defined as a decrease of >50 percent from the baseline Simple Endoscopic Score in Crohn disease [SES-CD] or for patients with isolated ileal disease and SES-CD of 4, at least a 2-point reduction from baseline) compared with placebo. Additionally, Skyrizi was associated with clinical remission (defined as a Crohn Disease Activity Index of less than 150) versus placebo, as both an induction and maintenance therapy. Clinical response and clinical remission were seen as early as week 4 in induction studies.
"In both the induction and maintenance clinical trials, a significantly greater number of adult patients saw few or no symptoms and a meaningful reduction of visible signs of intestinal inflammation, compared to placebo," Marla Dubinsky, M.D., a paid consultant and advisor for AbbVie, said in a statement. "This approval provides health care professionals with a greatly needed additional option for treating the disruptive symptoms of Crohn's disease."
Related Posts
Pasar más tiempo al aire libre podría reducir el riesgo de EM en los jóvenes
JUEVES, 9 de diciembre de 2021 (HealthDay News) -- Los niños que están en riesgo...
Meningitis Vaccine May Guard Against Gonorrhea
WEDNESDAY, April 13, 2022 (HealthDay News) -- Rates of gonorrhea are on the...
Pandemic Changed Families’ Eating Habits, for Good and Bad: Poll
TUESDAY, Sept. 21, 2021 (HealthDay News) -- Over the past year and a half, the...
Telehealth Services Use for Opioid Use Disorder Rose During Pandemic
FRIDAY, Sept. 16, 2022 (HealthDay News) -- Among Medicare beneficiaries, receipt...